Autopsy report · NCT03408405

ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children

“Withdrawal of funding from primary sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Rhode Island Hospital

Sponsor type

University, hospital or other

Conditions

Steroid-Resistant Nephrotic Syndrome

Interventions

Acthar Gel 80 UNT/ML Injectable Solution

Participants

0

Trials that died the same way

• Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple Myeloma
  “Funding withdrawn by sponsor” (89% match in meaning)
• Ultrasound Image Fusion for Placement of Sacral Quadripolar Leads
  “Sponsor withdrew funding” (88% match in meaning)
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
  “Withdrawal of sponsor support” (82% match in meaning)
• Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism
  “Withdrawal of sponsorship” (82% match in meaning)
• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod
  “Withdrawal of funding” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.